Does Semaglutide Come in Pill Form — and Is It Right for You?

How the pill form of semaglutide actually works

The semaglutide in Wegovy tablets is the same active molecule used in the injection, a GLP-1 receptor agonist that acts on appetite-regulating pathways in the brain and slows the rate at which the stomach empties. The key difference is how it gets into your bloodstream. Injected semaglutide is absorbed directly through subcutaneous tissue. The tablet uses a co-formulation with an absorption enhancer called SNAC, which allows a small but meaningful amount of semaglutide to cross the gut lining when the stomach is empty.

That last point matters practically. For the tablets to work, they need to be taken first thing in the morning on an empty stomach with a small sip of plain water, no more than about 120ml. You then wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. It's a short window, but it needs to be consistent. The NHS medicines information on semaglutide covers this clearly, and the patient information leaflet should be your definitive reference for the specifics.

Because absorption is lower than with the injection, the maintenance dose is much higher: 25mg daily for the tablet versus 2.4mg weekly for the standard injection. The two should not be compared dose-for-dose, they are calibrated differently for their respective routes. You can read more about how the pill form of semaglutide works in the body if the mechanism is something you want to understand fully before deciding.

What the trial results tell you, and what they don't

The phase 3 data behind Wegovy tablets came from a trial called OASIS 4, which ran for 64 weeks and included 307 adults with obesity or overweight plus at least one weight-related condition, all without diabetes. Participants taking the tablet alongside lifestyle changes lost an average of around 13.6% of their body weight, compared with roughly 2.4% on placebo. Among those who adhered fully to treatment throughout, the average reached about 17%.

That 17% figure is real, but context matters: it describes a subset who remained on treatment and followed the protocol consistently. The 13.6% figure is what you'd expect across the broader population in that trial. Both are meaningful. And both are lower than the roughly 15% average seen with the 2.4mg weekly injection in the STEP 1 trial, and some distance from tirzepatide's results, though direct comparisons between trials are imperfect because the populations and durations differ.

The most common side effects in OASIS 4 were gastrointestinal: nausea, diarrhoea and vomiting, reported by about 74% of participants on the tablet versus 42% on placebo. Most were mild to moderate and settled with time, especially after a dose increase. The titration schedule (spending at least a month at each dose level before moving up) exists largely to reduce this. Our Wegovy tablet overview covers the full side-effect picture in more detail.

The practical question: tablet or injection?

This is genuinely a clinical decision, not just a lifestyle preference. But there are real practical factors worth considering before you speak to a prescriber.

The tablet's biggest advantage is the absence of needles and no need for refrigeration. For people who travel frequently or feel strongly about injections, that removes a real barrier. The daily routine (tablet before anything else in the morning) suits people who have a consistent morning schedule. If your mornings are unpredictable, missing the 30-minute window occasionally could affect how well the medicine works.

The injection is once weekly, which some people find easier to remember and plan around. It also has a longer evidence base and is supported by more extensive real-world data. If you're already established on the 2.4mg weekly injection, your prescriber can assess whether switching to the semaglutide pill makes sense for you, that transition is possible but requires clinical review, not a self-directed swap.

Neither option is right for everyone. Pregnancy, breastfeeding, and trying to conceive are situations where neither form is recommended. The same applies to under-18s, for whom these medicines are not licensed. A prescriber looks at your full health picture (not just your BMI) before recommending a route. You can explore how Ozempic semaglutide tablets compare to other options, or look at the broader range of licensed weight-loss treatments available through nume if you're still weighing up your choices.

Getting the tablet on a private prescription in the UK

Wegovy tablets are not currently available on the NHS, a formal NICE appraisal would be needed first, and that process takes time. For now, the only route is a private prescription following a clinical assessment.

At nume, that assessment is carried out by a GPhC-registered Independent Prescriber who reads your consultation personally, not software, not a triage algorithm. If you meet the eligibility criteria and the prescriber is satisfied it's appropriate, a prescription is issued the same day. Orders placed before 12pm on a working day are dispatched the same day once approved, arriving the following working day in plain, unbranded packaging via DPD. You'll get a tracking link so you know exactly when to expect it. That matters for a daily tablet: knowing it's on its way means you can plan your morning routine without a gap.

The MHRA has also warned about semaglutide products being sold online by unverified sellers, sometimes without a clinical assessment at all. Any legitimate supplier should appear on the GPhC pharmacy register, nume's registration number is 9012878, verifiable directly. If a price looks unusually low or a seller doesn't ask any clinical questions, treat that as a warning sign rather than a bargain. For more on buying semaglutide tablets safely in the UK, we've covered the main things to look for.

If you'd like to understand more about whether semaglutide in oral form suits your situation, check your eligibility with our prescribers, the consultation is free, and there's no obligation to proceed.